You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

orelabrutinib

Showing 1 - 25 of 25
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Healthy Subject Trial in Beijing (Orelabrutinib and (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib

Active, not recruiting
  • Healthy Subject
  • Orelabrutinib and placebo (orelabrutinib tablet simulator)
  • +3 more
  • Beijing, China
    Beijing GoBroad Boren Hospital
Dec 19, 2022

Orelabrutinib in Treatment of Chronic Lymphocytic Leukemia/Small

Recruiting
  • CLL/SLL
  • Orelabrutinib
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital Affiliate
Jun 16, 2023

Orelabrutinib in Combination With Standard Treatment Regimen for

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
  • Orelabrutinib
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Aug 23, 2023

CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

Not yet recruiting
  • CNS Lymphoma
  • Orelabrutinib
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023

Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

Not yet recruiting
  • Relapsed/Refractory Marginal Zone Lymphoma
  • Orelabrutinib
  • +3 more
  • Guangzhou, Guangdong, China
  • +10 more
Oct 8, 2023

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +2 more
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

CLL/SLL Trial in Beijing (orelabrutinib)

Recruiting
  • CLL/SLL
  • orelabrutinib
  • Beijing, Beijing, China
  • +1 more
Aug 5, 2022

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Orelabrutinib
  • +2 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +3 more
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Orelabrutinib
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Orelabrutinib and Rituximab
  • Orelabrutinib
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

Diffuse Large B Cell Lymphoma Trial in Suzhou (Rituximab, Orelabrutinib, Pomalidomide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Apr 10, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +3 more
  • Beijing, Beijing, China
  • +2 more
May 19, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Orelabrutinib
  • +3 more
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022

Neuromyelitis Optica Spectrum Disorder Trial in Beijing (Orelabrutinib)

Not yet recruiting
  • Neuromyelitis Optica Spectrum Disorder
  • Orelabrutinib
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Mar 16, 2022

Immune Thrombocytopenia Trial in Beijing (Orelabrutinib)

Not yet recruiting
  • Immune Thrombocytopenia
  • Orelabrutinib
  • Beijing, Beijing, China
    Peking University Institute of Hematology
Nov 6, 2021

Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guangzhou (Orelabrutinib, Thiotepa)

Not yet recruiting
  • Refractory and Relapsed Primary CNS Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Aug 19, 2021

Immune Thrombocytopenia, Bruton's Tyrosine Kinase Trial (Orelabrutinib)

Not yet recruiting
  • Immune Thrombocytopenia
  • Bruton's Tyrosine Kinase
  • Orelabrutinib
  • (no location specified)
Aug 18, 2021

Primary CNS Hodgkin Lymphoma Trial in Hangzhou (Orelabrutinib, Sintilimab)

Recruiting
  • Primary Central Nervous System Hodgkin Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 14, 2021

Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Apr 24, 2022

Primary CNS Lymphoma Trial in Beijing (orelabrutinib, Sintilimab, Tislelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • orelabrutinib
  • +2 more
  • Beijing, Beijing, China
    Wei Zhang
May 19, 2021

Relapsing Remitting Multiple Sclerosis Trial in Worldwide (, orelabrutinib)

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • placebo
  • orelabrutinib
  • Ormond Beach, Florida
  • +41 more
Jan 28, 2022